Literature DB >> 30616806

Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations.

Luke R Smart1, Arielle G Hernandez2, Russell E Ware3.   

Abstract

The vast majority of the world's population of children and adults with sickle cell disease (SCD) are born in low-resource settings, particularly in sub-Saharan Africa, the Caribbean, the Middle East, and India. As a result numerous well-established, cost-effective, and evidence-based strategies for managing SCD such as newborn screening, early education, vaccinations, screening for stroke prevention, and treatments with safe transfusions and hydroxyurea are often unavailable, leading to substantial morbidity and increased mortality. Collaborations between high-income countries and these low-resource settings (North-South partnerships) have been advocated, with the goal of improving clinical care. Based on directives promulgated by the World Health Organization, we have developed a strategy of developing prospective research programs that focus on training, capacity building, and local data collection. This strategy involves consideration of important guiding principles, full partnerships, proper planning, and financial issues before program launch, after which rigorous program management is required for full effect and long-term sustainability. Ultimately these collaborative research programs should help create national guidelines and lead to improved clinical care for all children and adults with SCD.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Collaborative research; Global health; North-South partnerships; Sickle cell disease

Mesh:

Year:  2018        PMID: 30616806     DOI: 10.1053/j.seminhematol.2018.04.010

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  5 in total

Review 1.  What is the future of patient-reported outcomes in sickle-cell disease?

Authors:  Sharon A Singh; Nitya Bakshi; Prashant Mahajan; Claudia R Morris
Journal:  Expert Rev Hematol       Date:  2020-10-15       Impact factor: 2.929

2.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

3.  Empowering newborn screening programs in African countries through establishment of an international collaborative effort.

Authors:  Bradford L Therrell; Michele A Lloyd-Puryear; Kwaku Ohene-Frempong; Russell E Ware; Carmencita D Padilla; Emmanuela E Ambrose; Amina Barkat; Hassan Ghazal; Charles Kiyaga; Tisungane Mvalo; Obiageli Nnodu; Karim Ouldim; Mohamed Chérif Rahimy; Brígida Santos; Léon Tshilolo; Careema Yusuf; Guisou Zarbalian; Michael S Watson
Journal:  J Community Genet       Date:  2020-05-15

4.  Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics.

Authors:  Remi Cazelles; Rajendra P Shukla; Russell E Ware; Alexander A Vinks; Hadar Ben-Yoav
Journal:  Biomedicines       Date:  2020-12-24

Review 5.  Effective use of hydroxyurea for sickle cell anemia in low-resource countries.

Authors:  Alexandra Power-Hays; Russell E Ware
Journal:  Curr Opin Hematol       Date:  2020-05       Impact factor: 3.218

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.